Literature DB >> 34615692

The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival.

Benjamin Steinhart1, Kimberly R Jordan2, Jaidev Bapat3, Miriam D Post4, Lindsay W Brubaker5, Benjamin G Bitler6,7, Julia Wrobel8.   

Abstract

Ovarian cancer is the deadliest gynecologic malignancy. Multi-omics techniques have provided a platform for improved predictive modeling of therapy response and patient outcomes. While high-grade serous carcinoma (HGSOC) tumors are immunogenic and numerous studies have defined positive correlation to immune cell infiltration, immunotherapies in clinical trials have exhibited low efficacy rates. There is a significant need to better comprehend the role and composition of immune cells in mediating ovarian cancer therapeutic response and progression. We performed multiplex IHC with an HGSOC tissue microarray (n = 127) to characterize the immune cell composition within tumors. After analyzing the composition and spatial context of T cells (CD4/CD8), macrophages (CD68), and B cells (CD19) within the tumor, we found that increased B-cell and CD4 T-cell presence correlated with overall survival. More importantly, we observed that the proximity between tumor-associated macrophages and B cells or CD4 T cells significantly correlated with overall survival. IMPLICATIONS: The results highlight the antitumor role of B cells and CD4 T cells, and that the spatial interactions between immune cell types are a novel predictor of therapeutic response and patient outcomes. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34615692      PMCID: PMC8642308          DOI: 10.1158/1541-7786.MCR-21-0411

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  23 in total

1.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Authors:  Anne Montfort; Oliver Pearce; Eleni Maniati; Benjamin G Vincent; Lisa Bixby; Steffen Böhm; Thomas Dowe; Edmund H Wilkes; Probir Chakravarty; Richard Thompson; Joanne Topping; Pedro R Cutillas; Michelle Lockley; Jonathan S Serody; Melania Capasso; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

3.  Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.

Authors:  Chunyan Lan; Xin Huang; Suxia Lin; Huiqiang Huang; Qichun Cai; Ting Wan; Jiabin Lu; Jihong Liu
Journal:  Technol Cancer Res Treat       Date:  2012-12-26

Review 4.  B Cells as an Immune-Regulatory Signature in Ovarian Cancer.

Authors:  Prachi Gupta; Changliang Chen; Pradeep Chaluvally-Raghavan; Sunila Pradeep
Journal:  Cancers (Basel)       Date:  2019-06-26       Impact factor: 6.639

5.  The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval.

Authors:  Kimberly R Jordan; Matthew J Sikora; Jill E Slansky; Angela Minic; Jennifer K Richer; Marisa R Moroney; Junxiao Hu; Rebecca J Wolsky; Zachary L Watson; Tomomi M Yamamoto; James C Costello; Aaron Clauset; Kian Behbakht; T Rajendra Kumar; Benjamin G Bitler
Journal:  Clin Cancer Res       Date:  2020-09-14       Impact factor: 12.531

6.  Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.

Authors:  Alejandro Jiménez-Sánchez; Paulina Cybulska; Katherine LaVigne Mager; Simon Koplev; Oliver Cast; Dominique-Laurent Couturier; Danish Memon; Pier Selenica; Ines Nikolovski; Yousef Mazaheri; Yonina Bykov; Felipe C Geyer; Geoff Macintyre; Lena Morrill Gavarró; Ruben M Drews; Michael B Gill; Anastasios D Papanastasiou; Ramon E Sosa; Robert A Soslow; Tyler Walther; Ronglai Shen; Dennis S Chi; Kay J Park; Travis Hollmann; Jorge S Reis-Filho; Florian Markowetz; Pedro Beltrao; Hebert Alberto Vargas; Dmitriy Zamarin; James D Brenton; Alexandra Snyder; Britta Weigelt; Evis Sala; Martin L Miller
Journal:  Nat Genet       Date:  2020-06-01       Impact factor: 38.330

Review 7.  Do multiple outcome measures require p-value adjustment?

Authors:  Ronald J Feise
Journal:  BMC Med Res Methodol       Date:  2002-06-17       Impact factor: 4.615

Review 8.  Tumor-associated macrophages contribute to tumor progression in ovarian cancer.

Authors:  Emily K Colvin
Journal:  Front Oncol       Date:  2014-06-06       Impact factor: 6.244

Review 9.  Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.

Authors:  Fulvio Borella; Eleonora Ghisoni; Gaia Giannone; Stefano Cosma; Chiara Benedetto; Giorgio Valabrega; Dionyssios Katsaros
Journal:  Diagnostics (Basel)       Date:  2020-03-07
View more
  1 in total

1.  Tumor immune cell clustering and its association with survival in African American women with ovarian cancer.

Authors:  Christopher Wilson; Alex C Soupir; Ram Thapa; Jordan Creed; Jonathan Nguyen; Carlos Moran Segura; Travis Gerke; Joellen M Schildkraut; Lauren C Peres; Brooke L Fridley
Journal:  PLoS Comput Biol       Date:  2022-03-02       Impact factor: 4.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.